Competing with precision: incentives for developing predictive biomarker tests
dc.contributor.author | Brekke, Kurt R. | |
dc.contributor.author | Dalen, Dag Morten | |
dc.contributor.author | Straume, Odd Rune | |
dc.date.accessioned | 2022-04-05T09:13:33Z | |
dc.date.available | 2022-04-05T09:13:33Z | |
dc.date.issued | 2022-03 | |
dc.identifier.issn | 0804-6824 | |
dc.identifier.uri | https://hdl.handle.net/11250/2989856 | |
dc.description.abstract | We study the incentives of drug producers to develop predictive biomarkers, taking into account strategic interaction between drug producers and health plans. For this purpose we develop a two-dimensional spatial framework that allows us to capture the informational role of biomarkers and their effects on price competition and treatment choices. Although biomarkers increase the information available to prescribers, we identify an anticompetitive effect on the prices set by producers of therapeutically substitutable drugs. We also nd that better information about each patient s most therapeutically appropriate drug does not necessarily lead to more efficient treatment outcomes. | en_US |
dc.language.iso | eng | en_US |
dc.relation.ispartofseries | SAM DP;06/2022 | |
dc.title | Competing with precision: incentives for developing predictive biomarker tests | en_US |
dc.type | Working paper | en_US |
dc.source.pagenumber | 47 | en_US |
Tilhørende fil(er)
Denne innførselen finnes i følgende samling(er)
-
Discussion papers (SAM) [649]